Study of Zonegran for Epilepsy published in EJPN-Eisai
The safety profile of adjunctive Zonegran (zonisamide), from Eisai, in paediatric patients with partial Epilepsy is confirmed by pooled data published in the European Journal of Paediatric Neurology. These newly published safety data from 17 studies support zonisamide's proven clinical efficacy in children aged six years and above. The pooled analysis includes a total of 398 children who received zonisamide and 109 received placebo.
Most treatment emergent adverse events (TEAEs) were of mild or moderate intensity, the majority of which are already described in the safety profile for zonisamide. The most frequent treatment-related TEAEs were decreased appetite (15.6%), somnolence (12.1%), fatigue (9.3%), dizziness (6.0%), decreased weight (5.8%), irritability (5.8%) and headache (5.3%). The incidence of TEAEs that led to discontinuation was low 10.3%.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins